Jardiance's CV Benefit: Can A Single Study Carry The Day At FDA?
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency finds support for cardiovascular mortality benefit with Boehringer/Lilly's diabetes drug, but advisory committee will review weaknesses in outcomes trial's component data.